Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions
Synthetic Human Parathyroid Hormone 1-34 pump
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
7 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced May 21, 2026, 11:24 PM EDT
Conditions
DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome, Complete Atypical DiGeorge Syndrome
Interventions
Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw, Rabbit anti-thymocyte globulin, Cyclosporine, Tacrolimus, Methylprednisolone or Prednisolone, Daclizumab, Mycophenolate mofetil
Biological · Other · Procedure + 1 more
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced May 21, 2026, 11:24 PM EDT
Active, not recruiting No phase listed Observational
Conditions
Autosomal Dominant Hypocalcemia
Interventions
Not listed
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
Up to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
9
States / cities
Oakland, California • Aurora, Colorado • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Hypoparathyroidism
Interventions
rhPTH (1-84), Placebo
Biological
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Chicago, Illinois • Detroit, Michigan • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Autosomal Dominant Hypocalcemia (ADH)
Interventions
Encaleret, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
16 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Oakland, California • Aurora, Colorado • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Cytomegalovirus Infections, HIV Infections, Hypocalcemia
Interventions
Magnesium sulfate, Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
Interventions
SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Healthy Apheresis Donors
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced May 21, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available
Conditions
DiGeorge Anomaly, DiGeorge Syndrome, Complete DiGeorge Anomaly, Complete DiGeorge Syndrome
Interventions
Cultured Thymus Tissue Implantation (CTTI), Cultured Thymus Tissue Implantation with Parathyroid Transplantation
Biological · Other
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Thyroid Neoplasms, Thyroid Diseases, Hypoparathyroidism, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms by Site, Neoplasms, Head and Neck Neoplasms, Parathyroid Diseases
Interventions
PTeye
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions
Encaleret
Drug
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
0 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Hypocalcemia
Interventions
Amending current standard trauma order set
Diagnostic Test
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Hypocalcemia
Interventions
paricalcitol injection (Zemplar), Effects on calcium regulation, Administration of elemental Ca during hypocalcemic ICU pts.
Drug · Behavioral
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
9
States / cities
Merced, California • Denver, Colorado • Hudson, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
45
States / cities
Mobile, Alabama • Azusa, California • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Autosomal Dominant Hypocalcemia (ADH)
Interventions
NPSP795
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced May 21, 2026, 11:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers
Conditions
Secondary Hyperparathyroidism, Hypocalcemia
Interventions
Calcitriol
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Thyroid Nodules, Hypocalcemia
Interventions
Calcitriol, Control Pill
Dietary Supplement
Lead sponsor
David Shonka, MD
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 86 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Postpartum Hemorrhage, Pregnancy Related, Hypocalcemia, Parturition Complication
Interventions
Calcium Gluconate, Calcium chloride
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Alhambra, California • Azusa, California • Bakersfield, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Autosomal Dominant Hypocalcemia (ADH), Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions
Encaleret
Drug
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
16 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced May 21, 2026, 11:24 PM EDT
Conditions
Hypocalcemia, Pseudohypoparathyroidism, Osteomalacia, Rickets, Pseudopseudohpoparathyroidism
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Months to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced May 21, 2026, 11:24 PM EDT
Terminated Phase 2 Interventional Results available
Conditions
Hypocalcemia, Rickets
Interventions
1,25-Dihydroxycholecalciferol
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1976 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced May 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers
Conditions
Healthy
Interventions
magnesium
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 21, 2026, 11:24 PM EDT